MALVERN, Pa., Jan. 2, 2019 /PRNewswire/ -- TELA Bio®, Inc., a surgical reconstruction company leading the development andcommercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that Nora Brennan has joined the company as chief financial officer.
"It is our pleasure to welcome Ms. Brennan
Ms. Brennan brings more than 20 years of finance experience to TELA Bio, including capital markets and investor relations, with a focus on advising healthcare companies on financing strategies to support growing global and domestic operations. Prior to joining TELA Bio, Ms. Brennan served as the chief financial officer at Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company, where she oversaw the finance function and execution of the company strategy, including a $75 million initial public offering (IPO). Prior to Xeris, she was employed at Integra Lifesciences Corporation (IART), a global medical device company, where she held various senior leadership roles, including Senior Vice President, Investor Relations and Corporate Treasurer. Ms. Brennan holds a Master of Business Administration degree from the University of Chicago Booth School of Business and a Bachelor of Arts from the University of Illinois.
"TELA Bio has a unique opportunity to capitalize on a significant unmet need for cost-effective solutions within the hernia repair space, and I look forward to supporting the company's ability to successfully scale our infrastructure and financial planning for many years to come," said Ms. Brennan.
About TELA Bio, Inc.
TELA Bio, Inc. is a privately-owned company focused on bringing innovative, cost-effective, surgical reconstruction solutions to surgeons, hospitals and patients. The company's OviTex Reinforced BioScaffolds (RBSs) products, designed for hernia repair and abdominal wall reconstruction procedures, integrate polymer and biologic materials in a uniquely embroidered construction using novel engineering design principles. The OviTex portfolio is supported by high-quality, data-driven science and extensive pre-clinical research that has consistently demonstrated the advantages of an RBS over commercially available products. OviTex RBSs are commercially available in the U.S. and in Europe. The company is collaborating with leading surgeons to drive rapid product development and establish TELA Bio as a leader in surgical reconstruction. To learn more about TELA Bio visit http://www.telabio.com.
About OviTex Reinforced BioScaffolds
OviTex Reinforced BioScaffolds (RBSs) are intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. Indications for use include the repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome.
Do not use OviTex RBSs in patients known to be sensitive to materials of ovine (sheep) origin. For additional important safety information, please see the OviTex RBSs Instructions for Use.
The statements made or results achieved by TELA Bio customers described herein were achieved in their specific setting. Due to variations in clinical experience and technique, there is no guarantee that these results are typical. Bench testing may not be indicative of clinical performance.
Caution: Federal (US) law restricts this device to sale by or on order of a physician.
TELA Bio, Inc. owns or has applied for the following trademarks or service marks: OviTex, TELA Bio.
Media contactAdam Daley Berry & Company Public Relations212email@example.com
View original content:http://www.prnewswire.com/news-releases/nora-brennan-joins-tela-bio-as-chief-financial-officer-300771524.html
SOURCE TELA Bio, Inc.
Subscribe to our Free Newsletters!